cvs caremark - Search News

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

MinnPost · 1h

FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%

Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.

Becker's Hospital Review · 1d

FTC finds top 3 PBMs inflated drug prices by $7.3B

The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.

Seeking Alpha on MSN · 1d

FTC finds PBMs excessively marked up prices on specialty drugs

A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.

1hon MSN

UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Healthcare Dive7d

CVS successfully converts commercial pharmacy contracts to “cost plus” model

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Fierce Healthcare13d

Payer Roundup—More CVS layoffs after failed Medicaid bid

Below is a roundup of payer-centric news headlines you may have missed during the month of December 2024 and over the ...

Hosted on MSN3h

FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

Nasdaq8d

Zydus announces agreement with CVS Caremark

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Bernstein Sticks to Their Hold Rating for CVS Health (CVS)

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

money.rediff8d

Zydus Lifesciences Partners with CVS Caremark for Diabetes Drugs

Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...

Barchart on MSN1d

What You Need To Know Ahead of CVS Health's Earnings Release

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics